Heparin-Binding Epidermal Growth Factor shows reduced secretion from the preeclamptic placenta but is reversed by Rosiglitazone treatment. Secretion of Heparin-Binding Epidermal Growth Factor (HB-EGF) was measured via Luminex assay from conditioned media from non-treated control and preeclamptic (PE) placentas (A) and vehicle- or Rosiglitazone (Rosi)-treated PE placentas (B). There was a significant reduction of HB-EGF secretion from the PE placenta compared to control (A, n > 6). Rosi-treated PE placentas show a significant increase in HB-EGF secretion compared to the vehicle control (B, n = 10). (Protein secretion was measured by a Luminex assay where experimental values were determined relative to a standard curve. Statistical analysis was performed by student’s t-test to determine significant differences between groups, * p < 0.05, ** p < 0.01, bar plots and data reported are reported as mean pg/mL values ± SEM).